Celebrating the International Day of Women and Girls in Science
LifeArc celebrates this year's UN Day for Women and Girls in STEM.
Twitter outputted an error:
Invalid or expired token..
Invalid or expired token..
Alzheimer’s drug lecanemab approved by US regulator
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
2022 wrapped – our highlights from a pivotal year
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
MND Collaborative Partnership cautiously welcomes new Government funding
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.
Repurposed flu medicine could help under 60s recover faster from COVID-19
Results of an international repurposing study show favipiravir could help with COVID-19.
LifeArc bolsters executive team with communications expertise
Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer.
LifeArc plays key role in discovery of new Alzheimer’s treatment
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.
LifeArc contributes to organic chemistry breakthrough
The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS